References
- Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–1733.
- Kanis JA, Odén A, McCloskey EV, IOF Working Group on Epidemiology and Quality of Life, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–2256.
- Adult Official Positions of the ISCD as updated in 2019. www.iscd.org. Last assessed July 2021.
- Kanis JA, Johansson H, Harvey NC, et al. A brief history of FRAX. Arch Osteoporos. 2018;13(1):118.
- Kanis JA, Johansson H, Strom O, National Osteoporosis Guideline Group, et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19(10):1395–1408.
- Bone HG, Wagman RG, Brandi ML, et al. 10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.
- Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059–1064.
- Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512–514.
- American Cancer Society. Survival Rates for Breast Cancer. Available at: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html.
- Lorentzon M, Johansson H, Harvey NC, et al. Osteoporosis and fractures in women: the burden of disease. Climacteric. 2022;25(1):4–10.
- McCloskey EV, Harvey NC, Johansson H, et al. Fracture risk assessment by the FRAX model. Climacteric. 2022;25(1):22–28.
- Chandran M, Kwee A. Treatment indications and thresholds of intervention: consensus and controversies in osteoporosis. Climacteric. 2022;25(1):29–36.
- Reid IR. Bone-friendly lifestyle and the role of calcium or vitamin D supplementation. Climacteric. 2022;25(1):37–42.
- Jiang X, Kagan R. Hormone therapy for postmenopausal osteoporosis management. Climacteric. 2022;25(1):50–55.
- Palacios S. Medical treatment of osteoporosis. Climacteric. 2022;25(1):43–49.
- Goldstein SR. Selective estrogen receptor modulators and bone health. Climacteric. 2022;25(1):56–59.
- McClung MR, Clark AL. Osteoanabolic therapy for osteoporosis in women. Climacteric. 2022;25(1):60–66.
- Conradie M, de Villiers T. Premenopausal osteoporosis. Climacteric. 2022;25(1):73–80.
- Stevens Z, Hellig J. Breast cancer therapy and bone. Climacteric. 2022;25(1):67–72.
- Vasanwala RF, Gani L, Ang SB. It starts from the womb: maximizing bone health. Climacteric. 2022;25(1):11–21.
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis–report of the european working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–423.
- Mandelli A, Tacconi E, Levinger I, et al. The role of estrogens in osteosarcopenia: from biology to potential dual therapeutic effects. Climacteric. 2022;25(1):81–87.
- Laskou F, Patel HP, Cooper C, et al. A pas de deux of osteoporosis and sarcopenia: osteosarcopenia. Climacteric. 2022;25(1):88–95.